View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Technology
February 7, 2010

Arrhythmia Introduces OEM Version Of Predictor SAECG Software

Arrhythmia Research Technology (Arrhythmia) has successfully converted its proprietary signal-averaged electrocardiography (SAECG) software Predictor that runs on a single hardware based platform, ART 1200-EPX, to a customisable modular software product that is reconfigurable for a variety of hardware platforms.

By CBR Staff Writer

The conversion allows Predictor to be used with customer-specific electrocardiogram acquisition equipment to generate the signal-averaged ECG. The software can be easily customised to interface with a variety of Original Equipment Manufacturer (OEM) hardware. OEM customers can license Predictor and bundle it with other cardiac diagnostic software packages incorporated in their acquisition equipment.

The company said that a signal-averaged electrocardiogram detects cardiac microvolt signals. Signal averaging, which improves the signal to noise ratio, is a well-recognised technique for detecting and analysing such cardiac microvolt signals. High resolution acquisition equipment is used to collect the microvolt signals and transfer the data to an analytical system. ART’s patented Predictor software embedded in the system then filters and analyses the data to present the signal-averaged ECG for interpretation by a cardiologist.

James Rouse, president and CEO of Arrhythmia, said: We are very pleased to announce the availability of the Predictor SAECG analysis software to the OEM market. The patented methodology used in Predictor is considered by the American College of Cardiology and the American Heart Association to be the ‘Gold Standard’ in signal-averaged electrocardiography analysis.

“It is a very valuable risk stratification tool for electrophysiologists and cardiologists in the management of post myocardial infarction patients. Predictor is currently being used in a National Institutes for Health (NIH) funded investigation into ‘Risk Stratification in MADIT II Type Patients’.”

Content from our partners
How businesses can safeguard themselves on the cyber frontline
How hackers’ tactics are evolving in an increasingly complex landscape
Green for go: Transforming trade in the UK

Websites in our network
Select and enter your corporate email address Tech Monitor's research, insight and analysis examines the frontiers of digital transformation to help tech leaders navigate the future. Our Changelog newsletter delivers our best work to your inbox every week.
  • CIO
  • CTO
  • CISO
  • CSO
  • CFO
  • CDO
  • CEO
  • Architect Founder
  • MD
  • Director
  • Manager
  • Other
Visit our privacy policy for more information about our services, how New Statesman Media Group may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.
THANK YOU